Anavex Life Sciences has recently reported promising results from its Phase
2b/3 trial of blarcamesine, an investigational agent for treating early
Alzheimer’s disease. The trial demonstrated significant reductions in
pathological amyloid-ß levels and a slowing of brain atrophy, marking a notable
advancement in Alzheimer’s research.
Anavex study included 508 participants with early symptomatic Alzheimer’s,
randomized to receive either blarcamesine or a placebo for 48 weeks. The
Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) and the Alzheimer’s
Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) were used as
primary endpoints to evaluate cognitive and functional efficacy.
Patients treated with blarcamesine showed significant improvements in validated biomarkers of
amyloid-ß pathology. The plasma Aβ42/40 ratio demonstrated a strong antiamyloid
effect. MRI scans also showed a significant reduction in brain volume loss
compared to the placebo group, with the whole brain volume loss reaching statistical significance.
“The data are very exciting, particularly in a study that can demonstrate objective slowing
of markers of neurodegeneration,” said Dr. Michael Weiner, a noted expert
in radiology and biomedical imaging.
The most common treatment-emergent adverse event was dizziness, primarily mild to moderate and
transient in nature. This was reported by 35.8% of participants during the
titration phase and 25.2% during maintenance with blarcamesine.
According to Anavex Life Sciences, blarcamesine is a small oral molecule that exerts
clinical benefits on cognition and neurodegeneration, making it an appealing
treatment option. Dr. Christopher U Missling, CEO of Anavex, expressed his
gratitude to all involved in the study and emphasized the company’s commitment
to advancing Alzheimer’s treatment options.
Anavex Life Sciences continues to push the boundaries of neurodegenerative research, and
the promising results from the blarcamesine trial offer hope for a new,
effective treatment for Alzheimer’s disease. Refer to this article for related information.
Find more information about Anavex on https://www.linkedin.com/company/anavex-life-sciences